29
Fri, Mar
48 New Articles

Hengeler Mueller Advises on Fresenius Kabi Joint Venture

Russia
Tools
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

Hengeler Mueller announced that it advised Fresenius Kabi on its creation of a joint venture with CJSJ Binnopharm in Russia and CIS countries, initially reported by CEE Legal Matters on April 29, 2014.

Fresenius Kabi -- the German healthcare company based in Bad Homburg, will own 51% of the shares. Binnopharm is part of  Sistema JSFC -- one of the largest companies in Russia -- and provides intravenous drugs and infusion solutions and manufactures active pharmaceutical ingredients. The Moscow-based company has two manufacturing facilities, employs more than 350 people, and generated sales of USD 104 million in 2013. Zenitco Finance Management holds a minority stake in the company.

Fresenius Kabi has been active in the Russian market since 1994, and generated sales in Russia of USD 73 million last year. 

Hengeler Mueller advised Fresenius Kabi in tax matters in connection with the joint venture. Partners Ernst Thomas, Counsel Mathias Link, and Associate Steffen Horns led the team.

 

 

Our Latest Issue